Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape

Published:2021-08 Issue:4 Volume:6 Page:100204
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Adams E.,Wildiers H.^ORCID,Neven P.^ORCID,Punie K.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Breast cancer;Harbeck;Nat Rev Dis Prim,2019

3. How I treat metastatic triple-negative breast cancer;Caparica;ESMO Open,2019

4. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis;Poggio;ESMO Open,2018

5. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials—how to explain different results?;Franzoi;ESMO Open,2020

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer drugs imperil Asian tree species;Science;2024-09-13

2. Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers;Geburtshilfe und Frauenheilkunde;2024-09

3. UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan;Cancer Medicine;2024-08

4. Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans;Analytical Biochemistry;2024-07

5. Eribulin in breast cancer: Current insights and therapeutic perspectives;World Journal of Experimental Medicine;2024-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3